Dr Samra Turajlic is a Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust specialising in the treatment of kidney cancer and melanoma. She is a Cancer Research UK Clinician Scientist at the Francis Crick Institute and Associate Honorary Faculty at the Institute of Cancer Research, London.
Dr Turajlic completed her undergraduate studies in Physiological Sciences at Oxford University in 1999, and her clinical training at the University College London Medical School, qualifying in 2002. She gained a PhD in 2013 from the Institute of Cancer Research, University of London in the field of melanoma genetics and targeted therapy resistance.
She was awarded a Cancer Research UK Clinician Scientist Fellowship to continue laboratory research at the Francis Crick Institute, which she joined in 2014.
She completed specialist training in Medical Oncology in 2015 and was appointed as a Consultant on the Skin and Urology Units at The Royal Marsden.
She divides her time between the clinical work at The Royal Marsden and the Translational Cancer Therapeutics laboratory at the Francis Crick Institute. She is the Chief Clinical Investigator of translational studies into melanoma and kidney cancer and principle investigator on the PEACE study which examines cancer samples taken after death.
Dr Turajlic’s research goal is to understand how cancers evolve, in order to predict and circumvent treatment resistance. She has received funding grants from Harry J Lloyd Trust, Cancer Research UK, The Royal Marsden / ICR Biomedical Research Trust, and the Rosetrees Trust.